The activity of T-cell-mediated immunotherapies in B-cell lymphoma has been limited to date. The novel bispecific antibody CD20-TCB has a 2:1 antibody design to maximize T-cell engagement and demonstrates activity in preclinical models. This may represent a novel therapeutic approach for patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
Bibliographical notePublisher Copyright:
© 2018 American Association for Cancer Research.